{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:20:54Z","timestamp":1782958854774,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Brensocatib is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which activates several neutrophil serine proteases (NSPs), including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in the bone marrow during the early stage of neutrophil maturation. These NSPs are associated with pathogen destruction and inflammatory mediation; their dysregulated activation can result in excess secretion of active NSPs causing damaging inflammation and contributing to neutrophil-mediated inflammatory and autoimmune diseases. Pharmacological inhibition of DPP1 in the bone marrow could therefore represent an attractive strategy for these neutrophil-driven diseases. A completed Phase 2 trial in non-cystic fibrosis bronchiectasis patients (ClinicalTrials.gov number NCT03218917; EudraCT number: 2017-002533-32) indeed demonstrated that administration of brensocatib attenuated the damaging effects of chronic inflammation by inhibiting the downstream activation of NSPs. To support a range of preclinical programs and further understand how rodent species and strains may affect brensocatib\u2019s pharmacokinetic (PK) profile and its pharmacodynamic (PD) effects on NE, PR3, and CatG, an extensive na\u00efve dosing study with brensocatib at different dosing levels, frequencies, and durations was undertaken. Dose-dependent PK exposure responses (AUC and Cmax) were observed regardless of the rodent species and strain. Overall, mice showed greater reduction in NSP activities compared to rats. Both mice and rats dosed once daily (QD) had equivalent NSP activity reduction compared to BID (twice a day) dosing when the QD dose was 1.5-times the BID daily dose. For both mouse strains, CatG activity was reduced the most, followed by NE, then PR3; whereas, for both rat strains, PR3 activity was reduced the most, followed by CatG, and then NE. Maximum reduction in NSP activities was observed after \u223c7 days and recoveries were nearly symmetrical. These results may facilitate future <jats:italic>in vivo<\/jats:italic> brensocatib study dosing considerations, such as the timing of prophylactic or therapeutic administration, choice of species, dosage and dosing frequency.<\/jats:p>","DOI":"10.3389\/fphar.2023.1208780","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:00:14Z","timestamp":1689750014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species"],"prefix":"10.3389","volume":"14","author":[{"given":"Jessica","family":"Basso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"LaSala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle","family":"Dorfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Atalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Viramontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Leifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/1756-0500-5-401","article-title":"Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes","volume":"5","author":"Almansa","year":"2012","journal-title":"BMC Res. Notes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1538\/expanim.60.111","article-title":"Strain and sex differences in anxiety-like and social behaviors in C57BL\/6J and BALB\/cJ mice","volume":"60","author":"An","year":"2011","journal-title":"Exp. Anim."},{"key":"B3","volume-title":"Avoiding, minimizing, and alleviating distress. Recognition and alleviation of distress in laboratory animals","author":"Animals","year":"2008"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0272575","DOI":"10.1371\/journal.pone.0272575","article-title":"An optimized method of extracting and quantifying active Neutrophil serine proteases from human whole blood cells","volume":"17","author":"Basso","year":"2022","journal-title":"PLoS One"},{"key":"B5","first-page":"207","article-title":"The mighty mouse: The impact of rodents on advances in biomedical research","volume":"110","author":"Bryda","year":"2013","journal-title":"Mo Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: Results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Resp. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0172105","DOI":"10.1371\/journal.pone.0172105","article-title":"Neutrophils and neutrophil serine proteases are increased in the spleens of estrogen-treated C57BL\/6 mice and several strains of spontaneous lupus-prone mice","volume":"12","author":"Dai","year":"2017","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1701910","DOI":"10.1183\/13993003.01910-2017","article-title":"Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis","volume":"51","author":"Dittrich","year":"2018","journal-title":"Eur. Respir. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-1-59745-471-1_23","article-title":"Influence of genetic background on genetically engineered mouse phenotypes","volume":"530","author":"Doetschman","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"649693","DOI":"10.3389\/fimmu.2021.649693","article-title":"Neutrophils in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus: Same foe different M.O","volume":"12","author":"Fresneda Alarcon","year":"2021","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1111\/bph.13515","article-title":"Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity","volume":"173","author":"Gardiner","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00011-009-0054-2","article-title":"Mouse models of asthma: A comparison between C57bl\/6 and BALB\/c strains regarding bronchial responsiveness, inflammation, and cytokine production","volume":"58","author":"Gueders","year":"2009","journal-title":"Inflamm. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.physbeh.2018.01.024","article-title":"Behavioural characterization of C57BL\/6N and BALB\/c female mice in social home cage - effect of mixed housing in complex environment","volume":"188","author":"Heinla","year":"2018","journal-title":"Physiol. Behav."},{"key":"B16","first-page":"117","article-title":"Commonly used animal models","author":"Hickman","year":"2017","journal-title":"Princ. Animal Res. Graduate Undergrad. Students"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1021\/acs.jmedchem.9b00631","article-title":"Identification and optimization of novel cathepsin C inhibitors derived from EGFR inhibitors","volume":"62","author":"Hou","year":"2019","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.4049\/jimmunol.1201719","article-title":"Neutrophil extracellular traps: Double-edged swords of innate immunity","volume":"189","author":"Kaplan","year":"2012","journal-title":"J. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neubiorev.2014.05.011","article-title":"Consequences of psychophysiological stress on cytochrome P450-catalyzed drug metabolism","volume":"45","author":"Konstandi","year":"2014","journal-title":"Neurosci. Biobehav Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1021\/ml100212k","article-title":"Discovery of novel cyanamide-based inhibitors of cathepsin C","volume":"2","author":"Laine","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1517\/13543771003657172","article-title":"Inhibitors of cathepsin C (dipeptidyl peptidase I)","volume":"20","author":"Laine","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1152\/physiolgenomics.00185.2011","article-title":"Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstruction","volume":"44","author":"Livraghi-Butrico","year":"2012","journal-title":"Physiol. Genomics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20836","DOI":"10.1074\/jbc.M702615200","article-title":"Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing","volume":"282","author":"Methot","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1111\/bcp.13398","article-title":"Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)","volume":"83","author":"Miller","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","first-page":"740","article-title":"The response of C57BL\/6J and BALB\/cJ mice to increased housing density","volume":"48","author":"Nicholson","year":"2009","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/cpt.1053","article-title":"Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects","volume":"104","author":"Palmer","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","article-title":"Effect of stress on drug metabolism and its modulation by antistress agents","author":"Panagiotis Kourounakis","year":"2010"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.biocel.2007.11.008","article-title":"Neutrophil serine proteases fine-tune the inflammatory response","volume":"40","author":"Pham","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nri1841","article-title":"Neutrophil serine proteases: Specific regulators of inflammation","volume":"6","author":"Pham","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.mib.2014.11.002","article-title":"Neutrophil serine proteases in antibacterial defense","volume":"23","author":"Stapels","year":"2015","journal-title":"Curr. Opin. Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1093\/emboj\/20.23.6570","article-title":"Structure of human dipeptidyl peptidase I (cathepsin C): Exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J."},{"key":"B33","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1755-1536-6-18","article-title":"The role of mouse strain differences in the susceptibility to fibrosis: A systematic review","volume":"6","author":"Walkin","year":"2013","journal-title":"Fibrogenes. Tissue Repair"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez057.058","article-title":"The reversible dipeptidyl peptidase 1 inhibitor, INS1007, decreases surface proteinase 3 expression and neutrophil serine protease activities in human neutrophils","volume":"58","author":"Zhang","year":"2019","journal-title":"Rheumatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1208780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:00:22Z","timestamp":1689750022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1208780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":35,"alternative-id":["10.3389\/fphar.2023.1208780"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1208780","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"article-number":"1208780"}}